Compound 2
3-(furan-2-yl)-N-(5-(furan-2-yl)-2-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
From: Overcoming resistance to HER2 inhibitors through state-specific kinase binding
Synthetic procedure: See article for the definitive version of this procedure and for full experimental details.
2 was obtained in 66% yield over 2 steps as a white powder from 6 by a method similar to the one described for compound 1. MS (ES+) m/z 374.2 (M + H)+1; 1H NMR (DMSO-d6, 400 MHz) δ 4.02 (s, 3H), 6.60 (dd, 1H, J=3.3, 1.8Hz), 6.81 (dd, 1H, J=3.3, 0.7 Hz), 6.83 (dd, 1H, J=3.4, 1.8 Hz), 7.09 (dd, 1H, J=3.5, 0.7 Hz), 7.21 (d, 1H, J=8.7Hz), 7.45 (dd, 1H, J=8.5, 2.1Hz), 7.75 (dd, 1H, J=1.7, 0.6Hz), 8.02 (dd, 1H, J=1.8, 0.7Hz), 8.57 (s, 1H), 9.25 (d, 1H, J=2.2Hz), 9.64 (s, 1H), 14.05 (s, 1H); 13C NMR (DMSO-d6, 400 MHz) δ 56.97, 97.96, 104.93, 108.49, 111.7, 112.45, 113.15, 116.44, 119.34, 123.71, 128.84, 142.76, 143.88, 147.91, 148.54, 153.77, 154.03, 155.92, 156.15.
- PubChemID:
-
316894705
- MDL Molfile:
- ChemDraw:
